Analyst Research

Report Title Price
Provider: Stock Traders Daily
Provider: New Constructs, LLC
Provider: Wright Reports
Provider: S&P Capital IQ – STARS Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Teva Pharmaceutical Industries Ltd gives FY 2014 guidance

Tuesday, 10 Dec 2013 07:00am EST 

Teva Pharmaceutical Industries Ltd:Expects total net revenues (Generic Copaxone) of $19.3-$20.3 bln for FY 2014.Expects total net revenues (Exclusive Copaxone) $19.8-$20.8 bln for FY 2014.Expects EPS of $4.20-$4.50 (Generic Copaxone) for FY 2014.Expects EPS of $4.80-$5.10 (Exclusive Copaxone) for FY 2014.FY 2014 revenue of $19.9 bln and EPS of $4.91 - Thomson Reuters I/B/E/S Estimates.